Angiogenesis, Exudation, and Degeneration 2023 – Virtual Edition
A scientific education

Zum Kalender hinzufügen

Veranstaltung teilen

Zur Merkliste hinzufügen

Datum

10.02.2023, 07:50 - 11.02.2023, 14:10

Sprache

Englisch

Gebühren ab

100.00 EUR

Veranstalter

Bascom Palmer Eye Institute

Organisator

Bascom Palmer Eye Institute
1120 NW 14th Street, Suite 1563
US - 33136 Miami, Florida
Tel.: +1 (305) 326 6110

Fax: +1 (305) 326 6518

This Web-Seminar for retina specialists, general ophthalmologists and researchers will review the latest in imaging, translational research, and clinical trials with an emphasis on how these results will impact clinical ophthalmology. It will emphasize early phase clinical trials and recently completed studies focused on the treatment of a wide range of retinal diseases with special emphasis on AMD, diabetic retinopathy, uveitis, and retinal degeneration.

Basisinformation

Datum

10.02.2023, 07:50 - 11.02.2023, 14:10

Sprache

Englisch

Gebühren ab

100.00 EUR

Veranstalter

Bascom Palmer Eye Institute

Organisator

Bascom Palmer Eye Institute
1120 NW 14th Street, Suite 1563
US - 33136 Miami, Florida
Tel.: +1 (305) 326 6110

Fax: +1 (305) 326 6518

Programm

Course Objectives

Upon completion of this course, participants should be able to:

Examine new evidence for understanding the pathophysiology in nonexudative age-related macular degeneration
Examine new evidence for predicting disease progression in nonexudative age-related macular degeneration
Evaluate emerging therapies for the treatment of nonexudative age-related macular degeneration with a particular focus on complement inhibitors and the population most likely to benefit once these drugs are approved
Evaluate therapies targeting novel disease pathways being investigated in early-stage clinical trials for nonexudative age-related macular degeneration
Evaluate the clinical use of available anti-VEGF drugs for exudative ocular diseases
Provide an update on the next generation of anti-VEGF therapies recently approved and currently in development
Evaluate the benefits and limitations of different imaging technologies in the diagnosis and clinical management of macular and retinal diseases
Incorporate the latest advances in artificial intelligence, specifically machine learning, for the diagnosis and treatment of retinal diseases

Agenda

Friday, February 10, 2023

7:50 am	Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
	Session I: Non-Exudative AMD Moderators: Philip J. Rosenfeld, MD, PhD, Giovanni Gregori, PhD, and Zohar Yehoshua, MD, MHA Panelists: Gregory S. Hageman, PhD, Giovanni Staurenghi, MD, FARVO, FEBO, Christine A. Curcio, FARVO, Lawrence Singerman, MD, Aaron Y. Lee, MD, MSCI, R. Theodore Smith, MD, Giuseppe Querques, MD, Mengxi Shen, MD, Justis P. Ehlers, MD, and Baruch D. Kuppermann, MD, PhD
8:00	Age-Related Macular Degeneration: A Tale of Two Biologies Gregory S. Hageman PhD
8:10	High Resolution OCT of AMD Giovanni Staurenghi, MD, FARVO, FEBO
8:20	Imaging and Plasma Measures of Xanthophyll Carotenoids in Early Stages of AMD: Elucidating Lutein and Zeaxanthin Bioavailability in the ALSTAR2 Baseline Cohort Christine A. Curcio, PhD, FARVO
8:30	Short Form of the National Eye Institute Visual Function Questionnaire-25 {NEI VFQ-25}: The VFQ-7 Lawrence Singerman, MD
8:40	Deep Learning Techniques for AMD Biomarkers Aaron Y. Lee, MD, MSCI
8:50	Subretinal Drusenoid Deposits are Markers for Co-existent High-risk Vascular Diseases R. Theodore Smith, MD
9:00	Subclinical Age-Related Angioid Streaks with Pseudodrusen - A Frequent Cause of AMD Misdiagnosis Giuseppe Querques, MD
9:10	Correlations Between Central CC Flow Impairment and Cone Visual Acuity Measurements Mengxi Shen, MD
9:20	Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint Justis P. Ehlers, MD
9:30	Reversing Vision Loss in Dry AMD: Matching Mechanism with the Right Patient Population and Stage of Disease Baruch D. Kuppermann, MD, PhD
	Session II: Predicting Disease Progression in Non-Exudative AMD Moderators: Jaclyn L. Kovach, MD, Sander R. Dubovy, MD, and Philip J. Rosenfeld, MD, PhD Panelists: Frank G. Holz, FEBO, FARVO, David Sarraf, MD, Ruikang Wang, PhD, Philip J. Rosenfeld, MD, PhD, Pearse A. Keane, MD, MSc, FRCOphth MRCSI, Emily Y. Chew, MD, and Gemmy Cheung MBBS, FRCOphth, FAMS, MCI
9:40	MACUSTAR Study in Intermediate AMD: Novel Findings Frank G. Holz, FEBO, FARVO
9:50	Progression of iRORA to cRORA: Challenges in Implementation into Clinical Trials of AMD David Sarraf, MD
10:00	Automated Algorithms to Quantify Geographic Atrophy and Pigment Burden in AMD Ruikang Wang, PhD
10:10	The Onset and Progression of Persistent Hypertransmission Defects: A Novel Clinical Trial Endpoint for Studying iAMD Philip J. Rosenfeld, MD, PhD
10:20	Deep learning in Geographic Atrophy - the Impending Need for AI-enabled Therapeutics Pearse A. Keane, MD, MSc, FROphth, MRCSI
10:30	The Update of AREDS/AREDS2 on GA Progression and the Role of Reticular Pseudodrusen in AMD Progression Emily Y. Chew, MD
10:40	Macular Atrophy Phenotypes and Progression Rates in Asians Compared to Non-Asians Gemmy Cheung MBBS, FRCOphth, FAMS, MCI
	Session III: Therapies for Non-Exudative AMD Moderators: Ninel Z. Gregori, MD, Philip J. Rosenfeld, MD, PhD, and Raquel Goldhardt, MD, FACS Panelists: Pedro Lylyk, MD, Amir H. Kashani, MD, PhD, Arshad M. Khanani, MD, MA, David Eichenbaum, MD, David R. Lally, MD, FASRS, Glenn J. Jaffe, MD, Peter K. Kaiser, MD
10:50	Intracranial Ophthalmic Angioplasty (IOA): Safety and Preliminary Results, a Better Way to Improve Retinal and Choroidal Perfusion Pedro Lylyk, MD
11:00	Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy (GA) due to Age-Related Macular Degeneration Jeffrey S. Heier, MD
11:10	Preliminary Results of a Phase 1/2a Study Using Induced Pluripotent Stem Cell Derived Retinal Pigment Epithelium for Treatment of Advanced Dry Age Related Macular Degeneration with Geographic Atrophy Amir H. Kashani, MD, PhD
11:20	Results from the Phase II CATALINA Study Evaluating NGM621 for the Treatment of Geographic Atrophy Arshad M. Khanani, MD, MA
11:30	GATHER1/GATHER2: Comparison of Trial Design and Baseline Patient Populations Influencing Lesion Growth David Eichenbaum, MD
11:40	C5 Inhibition with Avacincaptad Pegol for the Treatment of Geographic Atrophy: Efficacy Results from the Phase 3 GATHER2 Trial David R. Lally, MD, FASRS
11:50	Foveal Invasion in GATHER2 Glenn J. Jaffe, MD
12:00 pm	Safety of the Phase 2/3 Gather1 and Gather2 Studies Peter K. Kaiser, MD
	Session IV: Pegcetacoplan Results for the Treatment of GA: Derby and Oaks Trials Moderators: Jorge Fortun, MD, Jayanth Sridhar, MD, and Philip J. Rosenfeld, MD, PhD Panelists: Eleonora M. Lad, MD, PhD, Rishi Singh, MD, Jeffrey S. Heier, MD, and Nadia K. Waheed, MD, MPH
12:10	2-year Outcomes of the Pegcetacoplan Phase 3 Derby and Oaks Clinical Trials for GA: Baseline Characteristics and Efficacy Eleonora M. Lad, MD, PhD
12:20	2-year Outcomes of the Pegcetacoplan Phase 3 Derby and Oaks Clinical Trials for GA: Safety and Exudative Changes Rishi Singh, MD
12:30	Analytical Strategies for Microperimetry in GA trials: The Oaks Trial Experience Nadia K. Waheed, MD, MPH
12:40	A Deeper Dive into the 24-Month Results of Derby and Oaks Trials Jeffrey S. Heier, MD
12:50	Panel Discussion: Derby and Oaks Trials
1:00	Session V Panel Discussion on Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD Moderators: Philip J. Rosenfeld MD, PhD Panelists: SriniVas R. Sadda, MD, Frank G. Holz, FEBO, FARVO, Emily Y. Chew, MD, Arshad M. Khanani, MD, MA, David Eichenbaum, MD, David R. Lally, MD, FASRS, Peter K. Kaiser, MD, Eleonora Lad, MD, PhD, Rishi Singh, MD, Jeffrey S. Heier, MD, Lawrence Singerman, MD, Giovanni Staurenghi, MD, and Nadia K. Waheed, MD, MPH
	Session VI: Exudative AMD Moderators: Luis J. Haddock, MD, Maura Di Nicola, MD, and Thomas A. Albini, MD Panelists: Richard F. Spaide, MD, SriniVas R. Sadda, MD, K. Bailey Freund, MD, Jean-Francois Korobelnik MD, PhD, Omer Trivizki, MD, MBA, Ursula Schmidt-Erfurth, MD, Anat Loewenstein, MD, Daniel F. Martin, MD, Nancy Holekamp, MD, and Usha Chakravarthy, MD
1:30	Inflammatory Cell Involvement in Neovascular Age-Related Macular Degeneration Richard F. Spaide, MD
1:40	OCT Risk Factors for Development of Macular Neovascularization SriniVas R. Sadda, MD
1:50	Deep Retinal Age-Related Microvascular Anomalies (DRAMA): A Mimic or Precursor of Intraretinal Neovascularization? K. Bailey Freund, MD
2:00	Exudation Assessment on SD-OCT in Wet AMD: B-Scan or Mapping? Jean-Francois Korobelnik MD, PhD
2:10	Remote Monitoring of Exudative AMD Patients using Macular Thickness Measurements and Optimal Change Thresholding Omer Trivizki, MD, MBA
2:20	Automated Quantification of Retinal Fluid in Real-World Disease Management Ursula Schmidt-Erfurth, MD
2:30	AI-Derived Fluid Dynamics in Exudative Retinal Diseases Anat Loewenstein, MD
2:40	Home OCT and its Potential Role in the Management of Neovascular AMD Daniel F. Martin, MD
2:50	Home OCT Guided Anti-VEGF Therapy in Patients with nAMD – First Longitudinal Study Results Nancy Holekamp, MD
3:00	Does Atrophy Precede or Follow Outer Retinal Fibrosis in Treated Neovascular AMD Usha Chakravarthy, MD
3:10	Adjourn until Saturday, Feb. 11th at 8:00 am

Saturday, February 11, 2023

7:50 am	Welcome and Overview Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
	Session VII: Emerging and Current Therapies for Exudative AMD Moderators: Janet L. Davis, MD, Thomas A. Albini, MD, and Nicolas A. Yannuzzi, MD Panelists: Tong Li, MD, PhD, Andrew A. Moshfeghi, MD, MBA, Xiaodong Sun, MD, PhD, Charles C. Wykoff, MD, PhD, Allen C. Ho, MD, Mark R. Barakat, MD, David M. Brown, MD, FACS, Carl D. Regillo, MD, Robyn Guymer, MBBS, PhD, and Seung-Young Yu, MD
8:00	LX102 Gene Therapy for Neovascular AMD Tong Li, MD, PhD
8:10	Update on a Hydrogel-Based Intravitreal Axitinib Intravitreal Implant (OTX-TKI) for the Treatment of Neovascular AMD Andrew A. Moshfeghi, MD, MBA
8:20	Primary Endpoint Results of a Phase II study of Efdamrofusp Alfa: A Bispecific Fusion Protein Targeting VEGF and Complement in Patients with nAMD: Multicentre, Randomized, Active Controlled Trial Xiaodong Sun, MD, PhD
8:30	An Update on Subretinal RGX-314 Gene Therapy in nAMD Charles C. Wykoff, MD, PhD
8:40	Long-Term Follow-Up of Durable Subretinal RGX-314 Gene Therapy for Exudative AMD Allen C. Ho, MD
8:50	Suprachoroidal Therapy for Neovascular AMD Mark R. Barakat, MD
9:00	Efficacy and Safety of High-Dose (8.0 mg) Aflibercept of Treatment for Wet AMD: 48-Week Results from PULSAR David M. Brown, MD, FACS
9:10	Talon Phase 3b Study Results: Brolucizumab vs. Aflibercept in a Matched Treat-and-Extend Superiority Study for Neovascular AMD Carl D. Regillo, MD
9:20	VOYAGER: An Innovative, Global, Observational Study to Gain Real-World Insights into the Long-term Utilisation of Faricimab and the Port Delivery System with Ranibizumab for the Treatment of nAMD and DME Robyn Guymer, MBBS, PhD
9:30	Three-Year Clinical Outcomes of Polypoidal Choroidal Vasculopathy Based on Swept-Source OCT Angiography Seung-Young Yu, MD
	Session VIII: Diabetic Retinopathy-Imaging and Treatment Moderators: Justin H. Townsend, MD, Harry W. Flynn, Jr. MD, and Basil Williams, MD Panelists: James G. Fujimoto, PhD, Toshinori Murata, MD, PhD, Peter K. Kaiser, MD, Peter A. Campochiaro, MD, Robert Bhisitkul, MD, PhD, Arshad M. Khanani, MD, MA, Dante Pieramici, MD, David S. Boyer, MD, Jennifer Sun MD, and Jayanth Sridhar, MD
9:40	OCT Angiography in Diabetic Retinopathy Harry W. Flynn, Jr. MD
9:50	Advances in Ultrahigh Speed SS-OCT Angiography for Assessing Retinal Blood Flow James G. Fujimoto, PhD
10:00	The Balance Between Leakage and Drainage in Macular Edema Toshinori Murata, MD, PhD
10:10	Efficacy and Safety data for APX3330, a novel oral drug candidate for DR/DME from the ZETA-1 Phase 2b trial Peter K. Kaiser, MD
10:20	Results of the Phase 2 BEHOLD Trial of UBX1325, A Novel Senolytic Agent for Diabetic Macular Edema Robert Bhisitkul, MD, PhD
10:30	Suprachoroidal Therapy for Diabetic Retinopathy Peter A. Campochiaro, MD
10:40	Port Delivery System with Ranibizumab (PDS) in Patients With Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pagoda Trial Arshad M. Khanani, MD, MA
10:50	Port Delivery System with Ranibizumab (PDS) in Patients With Diabetic Retinopathy: Primary Analysis Results of the Phase 3 Pavilion Trial Dante Pieramici, MD
11:00	Efficacy and Safety of High-dose (8 mg) Aflibercept for Treatment of DME: 48-Week Results from PHOTON David S. Boyer, MD
11:10	Results of DRCR Retina Network Protocol AC Jennifer Sun, MD
11:20	Changes in Prescribing Trends of Intravitreal Anti-Vascular Endothelial Growth Factor Antagonists with Initial Publication of DRCR.net Jayanth Sridhar, MD
	Session IX: Faricimab in Diabetic Retinopathy and Retinal Vein Occlusions Moderators: Harry W. Flynn, Jr. MD, Philip J. Rosenfeld, MD, PhD, and William E. Smiddy, MD Panelists: Karl G. Csaky, MD, PhD, Caroline Baumal, MD, Ramin Tadayoni, MD, PhD, Peter A. Campochiaro, MD, Robert Bhisitkul, MD, PhD, Arshad M. Khanani, MD, MA, Dante Pieramici, MD, David S. Boyer, MD, Jennifer Sun, MD, Jayanth Sridhar, MD, and Justin H. Townsend, MD
11:30	Faricimab in nAMD and DME - Latest Updates Caroline Baumal, MD
11:40	Ang2/VEGF Biology and Intraocular Suppression Following Intravitreal Administration of Faricimab Karl G. Csaky, MD, PhD
11:50	Faricimab in RVO - Results from the BALATON and COMINO Phase 3 Studies Ramin Tadayoni, MD, PhD
12:00 pm	Panel Discussion: Faricimab in Retinal Vascular Diseases
	Session X: Retinal Vascular Diseases and Uveitis Moderators: Thomas A. Albini MD, Stephen G. Schwartz, MD, MBA, and Philip J. Rosenfeld, MD, PhD Panelists: Darius M. Moshfeghi, MD, Michael S. Ip, MD, Diana V. Do, MD, Martin Friedlander, MD, PhD, Thomas A. Albini, MD, Lawrence A. Yannuzzi, MD, Steven Yeh, MD, and Sunil K. Srivastava, MD
12:10	Avascular Retina as the Risk Factor for Failure in BEAT ROP and anti-VEGF Clinical Trials Darius M. Moshfeghi, MD
12:20	Efficacy and Safety of Intravitreal Aflibercept versus Laser Photocoagulation for ROP: Results from the Phase 3 BUTTERFLEYE Trial Darius M. Moshfeghi, MD
12:30	Treatment Outcomes with Anti-VEGF Therapy for CRVO and BRVO: An Analysis of the Vestrum Database Michael S. Ip, MD
12:40	Update on KSI-301 and the BEACON Phase III Pivotal Study for Retinal Vein Occlusion Diana V. Do, MD
12:50	Results of the Phase 3 MacTel2 CNTF Trial Martin Friedlander, MD, PhD
1:00	Diagnostic Testing in Uveitis Thomas A. Albini, MD
1:10	Acute Zonal Occul Outer Retinopathy (AZOOR): Long-Term Follow-Up Lawrence A. Yannuzzi, MD
1:20	Integrated Analysis of Phase 3 Clinical Trials on Suprachoroidal Triamcinolone Acetonide for Macular Edema Due to Noninfectious Uveitis: From Evidence to Clinical Practice Steven Yeh, MD
1:30	Inflammatory Complications of Gene Therapy Sunil K. Srivastava, MD
	Session XI: Inherited Retinal Degenerations Moderators: Philip J. Rosenfeld MD PhD, Byron L. Lam MD, and Harry W. Flynn, Jr. MD Panelists: Carel B. Hoyng, MD, Quan Dong Nguyen, MD, MSc, and Byron L. Lam, MD
1:40	Stargardt Disease, Phenotyping, and Towards Clinical Trials Carel B. Hoyng, MD
1:50	Tinlarebant (LBS-008) for Stargardt Disease: The Story Continues Quan Dong Nguyen, MD, MSc
2:00	Treatments and Clinical Trials for Inherited Retinal Disease Byron L. Lam, MD
2:10	Post-Program Test and Closing Remarks

Gebühren

Fachärzte/-innen	Gebühren ab 100,00 EUR
Ärzte/-innen in Weiterbildung	Gebühren ab 100,00 EUR
Studenten/-innen	Gebühren ab 100,00 EUR
Orthoptisten/-innen	Gebühren ab 100,00 EUR
Sonstige	Gebühren ab 100,00 EUR

Buchung / Anmeldung

Registration required. Please contact the organizer for further information.
Zertifizierung
Zertifizierung beantragt für CME Punkte bei der Sonstige
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credits™.

Angiogenesis, Exudation, and Degeneration 2023 – Virtual Edition A scientific education

Angiogenesis, Exudation, and Degeneration 2023 – Virtual Edition A scientific education

Veranstaltung teilen

Ihr Account

Bitte einloggen

Bitte Status validieren

Angiogenesis, Exudation, and Degeneration 2023 – Virtual Edition
A scientific education

Angiogenesis, Exudation, and Degeneration 2023 – Virtual Edition
A scientific education